- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07933016
QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients
A Prospective, Single-arm, Phase II Clinical Study Was Conducted to Evaluate the Efficacy and Safety of QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients With Disease Progression Following First-line Immune-targeted Therapy
Liver cancer (hepatocellular carcinoma, HCC) is usually treated first with a combination of immunotherapy (drugs that help the immune system attack cancer) and targeted therapy (drugs that block signals cancer cells need to grow). However, many patients' cancer grows again after this first-line treatment, and currently available second-line single drugs shrink tumors in only about 5-15% of patients.
This study will test whether a new three-drug combination can work better as a second-line treatment. The combination includes: (1) QL1706 (iparomlimab and tuvonralimab), an investigational immunotherapy that blocks two immune "brakes" on cancer cells (PD-1 and CTLA-4) at the same time; (2) lenvatinib, an approved targeted-therapy capsule taken by mouth; and (3) FOLFOX, a standard chemotherapy combination given by infusion (oxaliplatin, levoleucovorin, and fluorouracil).
About 33 adults (18 years or older) with advanced HCC whose disease has worsened after first-line immune-targeted therapy will take part in this study at a single hospital in China. Participants will receive QL1706 by intravenous infusion once every 3 weeks, lenvatinib by mouth once daily, and FOLFOX chemotherapy every 3 weeks for up to 6 cycles. QL1706 and lenvatinib will continue as long as the cancer is controlled and side effects are acceptable, for up to 2 years.
The researchers hypothesize that the three-drug combination will shrink tumors in at least 30% of patients-clearly better than the approximately 10% response typically seen with currently available second-line single-drug treatments. The main outcome measure is the proportion of patients whose tumors shrink (objective response rate), assessed by the study doctors using standard imaging criteria (RECIST 1.1). The study uses a two-stage design: if the treatment appears ineffective after the first 10 patients are evaluated, the study will stop early.
Researchers will also measure how long the cancer stays under control, how long patients live, side effects, patients' quality of life, and whether blood markers can help predict who benefits from the treatment.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Background: First-line immune checkpoint inhibitor plus antiangiogenic targeted therapy is the standard of care for advanced hepatocellular carcinoma (HCC), but most patients eventually progress, and available second-line single agents achieve objective response rates (ORR) of only about 5%-15%. New strategies are needed for this population.
Design: This is a prospective, open-label, single-arm, single-center phase II trial at Sun Yat-sen Memorial Hospital, Sun Yat-sen University. Approximately 33 patients will be enrolled using a Simon optimal two-stage design (null ORR 10% vs. target ORR 30%; α = 0.05; power 80%). Stage 1 will treat 10 patients; the trial stops for futility if ≤1 patient responds; otherwise enrollment proceeds to 29 evaluable patients, and 33 patients will be enrolled allowing 10% dropout.
Interventions: QL1706 (iparomlimab and tuvonralimab, a PD-1/CTLA-4 antibody combination produced by MabPair technology) 5 mg/kg intravenously over 30 minutes on Day 1 of each 21-day cycle; lenvatinib 8 mg/day (body weight <60 kg) or 12 mg/day (≥60 kg) orally once daily; and FOLFOX every 3 weeks for up to 6 cycles (oxaliplatin 85 mg/m² IV over 2 hours; levoleucovorin calcium 200 mg/m² IV; fluorouracil 400 mg/m² IV bolus followed by 2400 mg/m² continuous infusion over 46 hours). QL1706 and lenvatinib continue until RECIST v1.1-confirmed progression (patients with continued clinical benefit may continue beyond initial progression), unacceptable toxicity, withdrawal of consent, or a maximum of 2 years of treatment.
Primary endpoint: investigator-assessed ORR per RECIST v1.1. Secondary endpoints: PFS, TTP, DCR, and DoR per RECIST v1.1 and mRECIST; surgical conversion rate in initially unresectable patients; OS and 12-/24-month OS rates; safety per NCI CTCAE v5.0; health-related quality of life (EORTC QLQ-C30 and QLQ-HCC18).
Exploratory: association between baseline chemotherapy-sensitivity genes (blood samples) and efficacy.
Key eligibility: age ≥18 years; histologically/cytologically or clinically confirmed HCC; BCLC stage B or C, unsuitable for surgery or locoregional therapy; progression after at least one prior line of immune-targeted therapy; ECOG PS 0-1; Child-Pugh A or B (≤7); ≥1 measurable lesion per RECIST v1.1; adequate organ function; life expectancy ≥12 weeks.
Timeline: start December 2026; last patient in December 2028; completion December 2029 (all anticipated).
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Linhui Peng, MD
- Telefoonnummer: +8619925780179 +8613710591214
- E-mail: 515332927@qq.com
Studie Contact Back-up
- Naam: Xiao Hu, MS
- Telefoonnummer: +8619925780179
- E-mail: 19925780179@163.com
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patient voluntarily agrees to participate in this study and provides written informed consent.
- Age ≥ 18 years; both male and female patients are eligible.
- Histologically or cytologically confirmed, or clinically diagnosed, hepatocellular carcinoma (HCC) prior to study treatment.
- Barcelona Clinic Liver Cancer (BCLC) stage B or C, and unsuitable for surgery or local-regional therapy, or disease progression after surgery and/or local-regional therapy.
- Local-regional therapy (including but not limited to surgery, radiotherapy, hepatic artery embolization, transarterial chemoembolization [TACE], hepatic arterial infusion, radiofrequency ablation, cryoablation, or percutaneous ethanol injection) completed at least 4 weeks prior to the baseline imaging scan (2 weeks for palliative radiotherapy), and all toxicities induced by local-regional therapy (excluding alopecia) must have recovered to ≤ Grade 1 per the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0).
- Documented disease progression or intolerance after at least one prior standard first-line immunotherapy and/or targeted therapy for HCC.
- At least one measurable lesion per RECIST v1.1 (the measurable lesion must have a longest diameter ≥ 10 mm on spiral CT scan, or a short-axis diameter ≥ 15 mm on CT scan for lymph node lesions; lesions previously treated with local-regional therapy may be selected as target lesions if clearly progressive per RECIST v1.1).
- Child-Pugh liver function class A, or good class B (score ≤ 7).
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Life expectancy ≥ 12 weeks.
- Adequate major organ function, meeting all of the following requirements (assessed within 7 days prior to initiation of study treatment):
- Hematology: absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L; platelet count (PLT) ≥ 75 × 10^9/L; hemoglobin ≥ 90 g/L;
- Serum biochemistry: albumin ≥ 25 g/L; total bilirubin ≤ 3.0 × upper limit of normal (ULN); alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 5 × ULN; creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance (CrCl) > 50 mL/min calculated by the Cockcroft-Gault formula: Male: CrCl = ((140 - age) × weight) / (72 × serum Cr); Female: CrCl = ((140 - age) × weight) / (72 × serum Cr) × 0.85 (weight in kg; serum Cr in mg/mL);
- International normalized ratio (INR) ≤ 2.3, or prothrombin time (PT) prolonged by ≤ 6 seconds above the normal control;
- Urine protein < 2+ (if urine protein ≥ 2+, 24-hour urine protein quantification may be performed; patients with 24-hour urine protein < 1.0 g are eligible).
- Patients with active hepatitis B virus (HBV) infection must receive anti-HBV therapy prior to initiation of study treatment and be willing to continue antiviral therapy throughout the entire study period; patients positive for hepatitis C virus (HCV) ribonucleic acid (RNA) must receive antiviral therapy according to local standard treatment guidelines, with liver function test elevations within CTCAE Grade 1.
- Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to study enrollment, must not be breastfeeding, and must agree to use contraception during the study period and for 6 months after the end of the study; male patients must agree to use contraception during the study period and for 6 months after the end of the study.
Exclusion Criteria:
- Known cholangiocarcinoma, sarcomatoid HCC, mixed-cell carcinoma (combined hepatocellular-cholangiocarcinoma), or fibrolamellar carcinoma; other active malignancy(ies) other than HCC within the past 5 years or concurrently. Patients with adequately treated localized tumors, such as basal cell carcinoma or squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, cervix, or breast, are eligible.
- Patients who are planning to undergo, or have previously undergone, organ or allogeneic bone marrow transplantation.
- Clinically symptomatic moderate or severe ascites requiring therapeutic paracentesis or drainage; uncontrolled pleural effusion or pericardial effusion of moderate volume or greater.
- History of gastrointestinal (GI) bleeding within 6 months prior to initiation of study treatment, or a definite tendency toward GI bleeding, such as: esophageal or gastric fundal varices at risk of bleeding or with severe varices, locally active GI ulcerative lesions, or persistently positive fecal occult blood; such patients are not eligible.
- Abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months prior to initiation of study treatment.
- Known hereditary or acquired hemorrhagic tendency (e.g., coagulation dysfunction) or thrombotic tendency.
- Currently receiving, or recently received (within 10 days prior to initiation of study treatment), aspirin > 325 mg/day (maximum antiplatelet dose), dipyridamole, ticlopidine, or cilostazol.
- Thrombotic or embolic events within 6 months prior to initiation of study treatment, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), pulmonary embolism, etc.
- Uncontrolled cardiac symptoms or diseases, such as: (1) heart failure of New York Heart Association (NYHA) Class II or above; (2) unstable angina pectoris; (3) myocardial infarction within 1 year; (4) clinically significant supraventricular or ventricular arrhythmia requiring clinical intervention; (5) hypertension inadequately controlled by medication, with a high risk of apatinib treatment as assessed by the investigator.
- Prior hypertensive crisis or hypertensive encephalopathy.
- Major vascular disease within 6 months prior to initiation of study treatment (e.g., aortic aneurysm requiring surgical repair, or recent peripheral arterial thrombosis).
- Severe, unhealed, or dehiscent wounds, active ulcers, or untreated bone fractures.
- Major surgery (excluding diagnostic procedures) within 4 weeks prior to initiation of study treatment, or anticipated major surgery during the study period.
- Inability to swallow tablets, malabsorption syndrome, or any condition affecting GI absorption.
- Intestinal obstruction within 6 months prior to initiation of study treatment, and/or clinical signs or symptoms of GI obstruction.
- Evidence of intra-abdominal free air that cannot be explained by paracentesis or recent surgical procedures.
- Prior or current central nervous system (CNS) metastases.
- History of hepatic encephalopathy.
- Current interstitial pneumonia or interstitial lung disease, or a history of interstitial pneumonia or interstitial lung disease requiring corticosteroid therapy; or other pulmonary conditions that may interfere with the assessment and management of immune-related pulmonary toxicity, such as pulmonary fibrosis, organizing pneumonia, pneumoconiosis, drug-induced pneumonitis, idiopathic pneumonitis, or severely impaired pulmonary function; active tuberculosis.
- Active autoimmune disease or a history of autoimmune disease with a risk of recurrence (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism [patients whose condition can be controlled by hormone replacement therapy alone are eligible]); patients with asthma requiring bronchodilator medical intervention are not eligible.
- Use of immunosuppressive agents or systemic corticosteroids for the purpose of immunosuppression (prednisone > 10 mg/day or equivalent doses of other corticosteroids) within 14 days prior to initiation of study treatment.
- Severe infection within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia; oral or intravenous therapeutic antibiotics within 2 weeks prior to initiation of study treatment (patients receiving prophylactic antibiotics, e.g., for prevention of urinary tract infection or chronic obstructive pulmonary disease exacerbation, are eligible).
- Congenital or acquired immunodeficiency (e.g., patients with HIV infection).
- Receipt of live attenuated vaccines within 28 days prior to initiation of study treatment, or anticipated need for such vaccination during camrelizumab treatment or within 60 days after the last dose of camrelizumab.
- Receipt of other investigational drugs within 28 days prior to initiation of study treatment.
- In the judgment of the investigator, any other factors that may affect the study results or lead to premature termination of the study, such as alcohol abuse or drug abuse, other serious illnesses (including psychiatric disorders) requiring concomitant treatment, severe laboratory abnormalities, or family or social factors that may compromise patient safety.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Experimental: QL1706 Plus Lenvatinib and FOLFOX Chemotherapy
Participants receive QL1706 (iparomlimab and tuvonralimab, a PD-1/CTLA-4 antibody combination) 5 mg/kg IV over 30 minutes on Day 1 of each 21-day cycle; lenvatinib 8 mg/day (body weight <60 kg) or 12 mg/day (≥60 kg) orally once daily; and FOLFOX every 3 weeks for up to 6 cycles: oxaliplatin 85 mg/m2 IV over 2 h, levoleucovorin calcium 200 mg/m2 IV, fluorouracil 400 mg/m2 IV bolus then 2400 mg/m2 IV infusion over 46 h, all on Day 1. When QL1706 and FOLFOX coincide, QL1706 is given first. QL1706 and lenvatinib continue until RECIST v1.1-confirmed progression, unacceptable toxicity, withdrawal of consent, or 2 years, whichever occurs first. For surgical conversion, lenvatinib is stopped 1 week before surgery; postoperative treatment follows pathological response. |
QL1706 (Iparomlimab and Tuvonralimab):5 mg/kg IV over 30 min on Day 1 Q3W until progression or 2 years.Lenvatinib :8 mg/day if <60 kg, 12 mg/day if >=60 kg; orally once daily.FOLFOX Chemotherapy:Oxaliplatin 85 mg/m2 + leucovorin + 5-FU IV Day 1 Q3W, max 6 cycles. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Objective Response Rate (ORR) per RECIST v1.1
Tijdsspanne: From first dose of study treatment to Week 104.
|
From first dose of study treatment until documented disease progression, death, or up to 2 years, whichever occurs first. |
From first dose of study treatment to Week 104.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-Free Survival (PFS) per RECIST v1.1
Tijdsspanne: From first dose of study treatment to Week 104
|
PFS is defined as the time from first dose of study treatment to the first documentation of disease progression per RECIST v1.1 or death from any cause, whichever occurs first, assessed by the investigator. |
From first dose of study treatment to Week 104
|
|
Overall Survival (OS)
Tijdsspanne: From first dose of study treatment to Week 104
|
OS is defined as the time from first dose of study treatment to death from any cause. Participants without documented death at the cutoff are censored at the date of last contact. |
From first dose of study treatment to Week 104
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Disease Control Rate (DCR) per RECIST v1.1
Tijdsspanne: From first dose of study treatment to Week 24
|
DCR is defined as the proportion of participants achieving confirmed complete response (CR), partial response (PR), or stable disease (SD) maintained for at least 6 weeks, as assessed by the investigator per RECIST v1.1. |
From first dose of study treatment to Week 24
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Neoplasmata per histologisch type
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Lever Ziekten
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Lever neoplasmata
- Carcinoom
- Carcinoom, hepatocellulair
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Coördinatiecomplexen
- Pyrimidines
- Uracil
- Pyrimidinonen
- Oxaliplatine
- Fluorouracil
Andere studie-ID-nummers
- SYSKY-2026-639-01
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The sponsor has no plan to share individual participant data (IPD). IPD will not be shared because the informed consent did not include authorization for public data sharing, and sharing could compromise participant privacy and confidentiality. De-identified, aggregate study results will be published in peer-reviewed journals and posted in public trial registries.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .